RxDoctor Payments Data

Jonathan McGehee, NP

Family · Spartanburg, SCNPI 1386308211

Payments from drug & device makers

$3,475in general payments, 2019–2025

Across 184 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$637
  • AbbVie$549
  • Johnson & Johnson$546
  • UCB, Inc.$284
  • GSK$272
  • Novartis$261
  • plus $926 from 16 others

What the payments were for

  • Food & beverage$3,475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,475 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$19,024
Medicare patients
172
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept36$267,296
Humira(Cf) PenAdalimumab34$232,786
RinvoqUpadacitinib37$223,678
Cosentyx Sensoready (2 Pens)Secukinumab19$157,074
Xeljanz XrTofacitinib Citrate21$120,040
Enbrel MiniEtanercept14$105,019
KevzaraSarilumab11$43,942
Celecoxib113$3,987
Hydroxychloroquine Sulfate100$3,093
MethotrexateMethotrexate Sodium114$2,661
Leflunomide35$1,668
Prednisone228$1,307
Diclofenac Sodium88$941
Colchicine20$690
Baclofen23$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$549$223,67837 claims
SanofiKevzara$21$43,94211 claims
Scilex Pharmaceuticals Inc.Colchicine$46$69020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →